TTR and cardiomyopathy: Accordingly, another GalNAc–siRNA conjugate targeting TTR, vutrisiran (ALN-TTRsc02), will be used to further explore the benefit–risk profile of RNAi therapeutics across the full spectrum of ATTR amyloidosis, including patients with hereditary and wt cardiomyopathy.